Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center
Advertisement
Articles by Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center
Advertisement
Latest Updated Articles
Metastatic Breast Cancer: Chemotherapy SelectionPublished: January 26th 2021 | Updated:
Assessing Response to Chemotherapy in Metastatic Breast CancerPublished: January 19th 2021 | Updated:
MBC Therapy: Tesetaxel/CapecitabinePublished: February 16th 2021 | Updated:
Treatment Advances in Metastatic Breast CancerPublished: January 19th 2021 | Updated:
Using Oral Therapies to Advance Care in MBCPublished: February 16th 2021 | Updated:
At-Home Administration of Therapies to Treat MBCPublished: February 9th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Oncology Fellows Highlights 2025 ESMO Fellowship Winners
5